These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 25643258

  • 1. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
    Li W, Zhao XL, Shang SQ, Shen HQ, Chen X.
    Curr Cancer Drug Targets; 2015; 15(3):196-204. PubMed ID: 25643258
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
    Natoni A, Murillo LS, Kliszczak AE, Catherwood MA, Montagnoli A, Samali A, O'Dwyer M, Santocanale C.
    Mol Cancer Ther; 2011 Sep; 10(9):1624-34. PubMed ID: 21768328
    [Abstract] [Full Text] [Related]

  • 3. Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML.
    O' Reilly E, Dhami SPS, Baev DV, Ortutay C, Halpin-McCormick A, Morrell R, Santocanale C, Samali A, Quinn J, O'Dwyer ME, Szegezdi E.
    Sci Rep; 2018 Oct 25; 8(1):15752. PubMed ID: 30361682
    [Abstract] [Full Text] [Related]

  • 4. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP, He J, van der Noord VE, Redel J, Foekens JA, Martens JWM, Smid M, Zhang Y, van de Water B.
    Breast Cancer Res; 2019 Jul 01; 21(1):77. PubMed ID: 31262335
    [Abstract] [Full Text] [Related]

  • 5. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
    Montagnoli A, Valsasina B, Croci V, Menichincheri M, Rainoldi S, Marchesi V, Tibolla M, Tenca P, Brotherton D, Albanese C, Patton V, Alzani R, Ciavolella A, Sola F, Molinari A, Volpi D, Avanzi N, Fiorentini F, Cattoni M, Healy S, Ballinari D, Pesenti E, Isacchi A, Moll J, Bensimon A, Vanotti E, Santocanale C.
    Nat Chem Biol; 2008 Jun 01; 4(6):357-65. PubMed ID: 18469809
    [Abstract] [Full Text] [Related]

  • 6. 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.
    Hu XY, Liang JY, Guo XJ, Liu L, Guo YB.
    Clin Exp Pharmacol Physiol; 2015 Feb 01; 42(2):146-53. PubMed ID: 25363523
    [Abstract] [Full Text] [Related]

  • 7. Targeting Inflammation, PHA-767491 Shows a Broad Spectrum in Protein Aggregation Diseases.
    Chung YH, Lin CW, Huang HY, Chen SL, Huang HJ, Sun YC, Lee GC, Lee-Chen GJ, Chang YC, Hsieh-Li HM.
    J Mol Neurosci; 2020 Jul 01; 70(7):1140-1152. PubMed ID: 32170713
    [Abstract] [Full Text] [Related]

  • 8. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
    Cho SJ, Lee SS, Kim YJ, Park BD, Choi JS, Liu L, Ham YM, Moon Kim B, Lee SK.
    Cancer Lett; 2010 Jan 28; 287(2):196-206. PubMed ID: 19616371
    [Abstract] [Full Text] [Related]

  • 9. A Dual Inhibitor of Cdc7/Cdk9 Potently Suppresses T Cell Activation.
    Chen EW, Tay NQ, Brzostek J, Gascoigne NRJ, Rybakin V.
    Front Immunol; 2019 Jan 28; 10():1718. PubMed ID: 31402912
    [Abstract] [Full Text] [Related]

  • 10. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
    Benten D, Keller G, Quaas A, Schrader J, Gontarewicz A, Balabanov S, Braig M, Wege H, Moll J, Lohse AW, Brummendorf TH.
    Neoplasia; 2009 Sep 28; 11(9):934-44. PubMed ID: 19724687
    [Abstract] [Full Text] [Related]

  • 11. Cdc7-dependent and -independent phosphorylation of Claspin in the induction of the DNA replication checkpoint.
    Rainey MD, Harhen B, Wang GN, Murphy PV, Santocanale C.
    Cell Cycle; 2013 May 15; 12(10):1560-8. PubMed ID: 23598722
    [Abstract] [Full Text] [Related]

  • 12. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Jiang H, Dong Q, Luo X, Shi B, Wang H, Gao H, Kong J, Zhang J, Li Z.
    Cancer Lett; 2014 Jan 01; 342(1):113-20. PubMed ID: 24007863
    [Abstract] [Full Text] [Related]

  • 13. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
    Xu L, Zhu Y, Shao J, Chen M, Yan H, Li G, Zhu Y, Xu Z, Yang B, Luo P, He Q.
    Br J Cancer; 2017 Apr 11; 116(8):1027-1036. PubMed ID: 28267710
    [Abstract] [Full Text] [Related]

  • 14. Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.
    Guo Y, Wang J, Benedict B, Yang C, van Gemert F, Ma X, Gao D, Wang H, Zhang S, Lieftink C, Beijersbergen RL, Te Riele H, Qiao X, Gao Q, Sun C, Qin W, Bernards R, Wang C.
    Genome Med; 2021 Oct 18; 13(1):166. PubMed ID: 34663432
    [Abstract] [Full Text] [Related]

  • 15. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds.
    Sasi NK, Tiwari K, Soon FF, Bonte D, Wang T, Melcher K, Xu HE, Weinreich M.
    PLoS One; 2014 Oct 18; 9(11):e113300. PubMed ID: 25412417
    [Abstract] [Full Text] [Related]

  • 16. Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma.
    Wang Z, Gu C, Wang X, Lang Y, Wu Y, Wu X, Zhu X, Wang K, Yang H.
    Med Oncol; 2019 Oct 29; 36(12):97. PubMed ID: 31664534
    [Abstract] [Full Text] [Related]

  • 17. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
    Zhang Y, Jia QA, Kadel D, Zhang XF, Zhang QB.
    Med Sci Monit; 2018 May 03; 24():2735-2743. PubMed ID: 29720580
    [Abstract] [Full Text] [Related]

  • 18. Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway.
    Chen XZ, Cao ZY, Chen TS, Zhang YQ, Liu ZZ, Su YT, Liao LM, Du J.
    Oncol Rep; 2012 Aug 03; 28(2):742-8. PubMed ID: 22641337
    [Abstract] [Full Text] [Related]

  • 19. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R, Basana A, Lupi M, Guffanti F, Gaudio E, Rinaldi A, Cascione L, Restelli V, Tarantelli C, Bertoni F, Damia G, Carrassa L.
    Oncotarget; 2015 Feb 20; 6(5):3394-408. PubMed ID: 25428911
    [Abstract] [Full Text] [Related]

  • 20. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach.
    Cheng AN, Lo YK, Lin YS, Tang TK, Hsu CH, Hsu JT, Lee AY.
    EBioMedicine; 2018 Oct 20; 36():241-251. PubMed ID: 30293817
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.